AstraZeneca Plc announced that it will voluntarily delist its American Depositary Shares from Nasdaq and will list its ordinary shares directly on the New York Stock Exchange (NYSE). The Nasdaq listings will cease after market close on January 30 2026, with NYSE trading of ordinary shares beginning on February 2 2026. The company’s ticker symbol, AZN, will remain unchanged and the shares will also be listed on the London Stock Exchange and Nasdaq Stockholm.
The move is part of a shareholder‑approved plan to harmonize AstraZeneca’s global listing structure into a single framework. By eliminating the 2‑for‑1 ADR ratio that has been in place for decades, the company will now offer a 1‑for‑1 direct listing of ordinary shares. This simplification is intended to broaden access for U.S. investors, including pension funds and institutional mandates that prefer to hold the same class of equity as investors in the UK and Sweden.
The transition was first announced on September 29 2025 and received shareholder approval in November 2025. The plan will allow the company to trade ordinary shares on three major exchanges—London, Stockholm, and New York—while removing the ADR layer. The ordinary shares have a par value of $0.25 and will trade under the same AZN ticker on all venues.
The delisting will also affect the Nasdaq‑100 index composition; Walmart is expected to replace AstraZeneca following the removal of its ADRs. The change is expected to unlock deeper capital pools and simplify the company’s capital stack, positioning AstraZeneca for broader institutional participation in the U.S. market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.